WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H526219
CAS#: 221529-58-4
Description: RO-1138452, also known as CAY10441, is a potent and selective IP antagonist. CAY10441 antagonizes the carbaprostacyclin-induced activation of human neuroblastoma adenylate cyclase, blocking cyclic AMP accumulation in a dose-dependent manner.
Hodoodo Cat#: H526219
Name: RO-1138452
CAS#: 221529-58-4
Chemical Formula: C19H23N3O
Exact Mass: 309.18
Molecular Weight: 309.410
Elemental Analysis: C, 73.76; H, 7.49; N, 13.58; O, 5.17
Synonym: RO-1138452; RO1138452; RO 1138452; CAY10441; CAY-10441; CAY 10441;
IUPAC/Chemical Name: N-(4-(4-isopropoxybenzyl)phenyl)-4,5-dihydro-1H-imidazol-2-amine4,5-Dihydro-N-(4-((4-(1-methylethoxy)phenyl)methyl)phenyl)-1H-imadazol-2-amine
InChi Key: GYYRMJMXXLJZAB-UHFFFAOYSA-N
InChi Code: InChI=1S/C19H23N3O/c1-14(2)23-18-9-5-16(6-10-18)13-15-3-7-17(8-4-15)22-19-20-11-12-21-19/h3-10,14H,11-13H2,1-2H3,(H2,20,21,22)
SMILES Code: CC(OC1=CC=C(C=C1)CC2=CC=C(NC3=NCCN3)C=C2)C
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, DMF, and ethanol
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 309.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Auberson YP, Briard E, Sykes D, Reilly J, Healy M. Ligand Specific Efficiency (LSE) Index for PET Tracer Optimization. ChemMedChem. 2016 Jul 5;11(13):1415-27. doi: 10.1002/cmdc.201600112. Epub 2016 May 19. PMID: 27193393.
2: Syed NI, Jones RL. Assessing the agonist profiles of the prostacyclin analogues treprostinil and naxaprostene, particularly their DP₁ activity. Prostaglandins Leukot Essent Fatty Acids. 2015 Apr;95:19-29. doi: 10.1016/j.plefa.2014.11.011. Epub 2014 Dec 5. PMID: 25542069.
3: McCormick C, Jones RL, Kennedy S, Wadsworth RM. Activation of prostanoid EP receptors by prostacyclin analogues in rabbit iliac artery: implications for anti-restenotic potential. Eur J Pharmacol. 2010 Sep 1;641(2-3):160-7. doi: 10.1016/j.ejphar.2010.04.035. Epub 2010 May 5. PMID: 20450909.
4: Clark RD, Jahangir A, Severance D, Salazar R, Chang T, Chang D, Jett MF, Smith S, Bley K. Discovery and SAR development of 2-(phenylamino) imidazolines as prostacyclin receptor antagonists [corrected]. Bioorg Med Chem Lett. 2004 Feb 23;14(4):1053-6. doi: 10.1016/j.bmcl.2003.10.070. Erratum in: Bioorg Med Chem Lett. 2004 May 17;14(10):2697. PMID: 15013022.
